SureTrader SureTrader
Home > Boards > US Listed > Biotechs >

Collabrx, Inc. (CLRX)

CLRX RSS Feed
Add CLRX Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board:
Last Post: 12/14/2015 9:35:05 AM - Followers: 27 - Board type: Free - Posts Today: 0

 

Informing Next Generation Healthcare

CollabRx is a data analytics company that uses cloud-based expert systems to inform healthcare decision-making by aggregating and contextualizing the world’s knowledge on molecular medicine with specific insights from the nation’s top clinical experts.

 

History

CollabRx was co-founded in 2008 by a Silicon Valley tech pioneer/survivor of metastatic cancer and a Stanford professor with an expertise in biocomputing and Artificial Intelligence. They understood from personal experience that incredible amounts of information was available to patients and physicians over the “Cancer Internet”, but very little of it was truly personalized, actionable, and expert vetted. Consider there are over 500 new therapies in clinical development, more than 10,000 cancer-related clinical trials, and over 100,000 papers on cancer published each year, and it’s rapidly changing all the time––making it impossible for any one person to keep up.

CollabRx was started with the goal of bridging this knowledge gap and providing easily accessible information to patients and physicians by applying advanced Artificial Intelligence techniques in combination with actual clinical experts (i.e., “expert systems”) to filter the world’s knowledge in molecular medicine down to essential, highly curated content.

 


Informing Next Generation Healthcare  CollabRx is a data analytics company that uses cloud-based expert systems to inform healthcare decision-making by aggregating and contextualizing the world’s knowledge on molecular medicine with specific insights from the nation’s top clinical experts.

 

Who We Are & What We Do

Clinically Relevant Interpretation of Big Data

CollabRx is a data analytics company that uses cloud-based expert systems to inform healthcare decision-making by aggregating and contextualizing the world’s knowledge on genomics-based medicine with specific insights from the nation’s top clinical experts.

That means we:

  • Recruit experts and key opinion leaders to lead Editorial Boards
    Find and analyze information on therapies, clinical trials and diagnostics
    Organize this information into standard and interactive frameworks known as Molecular Disease Models, which are published in peer-reviewed literature
    Convert information into knowledge and personalized therapy options
    Make knowledge and recommendations accessible through Web-based and mobile applications
    Dynamically update content to reflect continuous changes in the science and medicine

These activities result in products and services that support the unique needs of multiple healthcare markets.


Venn Diagram

Patients

Technology is revolutionizing how patients identify and act upon information that may be relevant for treating their particular condition or disease. Social networks are empowering patients, most notably those with cancer, and the Internet is making massive quantities of information accessible to everyone. Not only is it impossible for patients to keep up with the flood of information, there is also a notable lack of online resources that provide specific, actionable, and personalized therapy considerations that is both highly credible and current.

For patients, CollabRx provides actionable and highly credible information that can be shared with their physician in a form that supports collaborative decision making in determining a cancer treatment plan that is customized for them. Patients currently interact with the CollabRx knowledge base via Web-based applications.

Our initial product for empowered patients (Therapy Finder™ – Professional) is a series of Web-based expert systemapplications currently available for melanomacolorectal cancer, and lung cancer.

Physicians

Market surveys indicate that while 90% of physicians desire to practice personalized medicine, only 10% feel adequately prepared to do so. The ever-growing quantity of genomic and other molecular data has thus far outpaced their ability to keep track of all the therapeutically relevant options that are available. As a result, a knowledge gap has developed between the desire and ability to apply molecular profiling to inform personalized treatment options.

For physicians, CollabRx provides sophisticated, yet intuitive decision support tools that enable rapid and accurate determination of relevant medical tests, therapies, and clinical trials that may have gone overlooked otherwise. By leveraging CollabRx’s customizable cloud-based expert systems, physicians have access to the most up-to-date, and credible molecular-based data to support optimal decision making and treatment planning.

This universal access to next generation healthcare boosts enrollment in clinical trials, increases in-house knowledge and expertise, fosters collaborative environments, and encourages patient-physician engagement.

Payers

CollabRx provides expert-backed, transparent, current, and peer-reviewed knowledge to physicians and patients to inform treatment plans that support optimal clinical outcomes and are as cost-efficient as possible.

Our cancer products and services highlight the primary molecular tests for physicians to consider that have therapeutic implications and that take into consideration the unique genetic profile of patient tumors. This targeted therapy approach to cancer treatment results in therapy plans that are more likely to be effective.

NGS Providers

Thanks to technological advancements in next generation sequencing (NGS) that have reduced the time and cost to sequence entire genomes, the world is in the midst of a genetic information revolution. The ease and accuracy with which whole genomes can be sequenced is making genomics-based personalized medicine not only probable, but possible. When combined with patient medical records, the result is a dataset of unprecedented size and scope.

The sheer volume of data produced by NGS far exceeds the ability of individual physicians, drug developers and healthcare providers to stay up-to-date on its potential clinical relevance.

For NGS providers, CollabRx provides clinical interpretation of whole genome sequencing with an emphasis on what is actionable today based on the clinical strength of evidence linking observed mutations to therapy options, including drugs and clinical trials. As sequencing costs continue to fall, increased emphasis will be placed on the interpretation of sequencing data.

Biotech & Pharma

Biotechnology and pharmaceutical companies are increasingly developing drugs that target specific molecular abnormalities, particularly in oncology. CollabRx products and services provide awareness of approved drugs and diagnostics and those in clinical development.

CollabRx provides analytical services to pharma and biotech for business intelligence.

Laboratories

The number of molecular tests with therapeutic implications is rapidly increasing, particularly for cancer. Also, advances in next generation sequencing (NGS) platforms have made genetic sequencing less expensive, easier, and more accessible than ever before. As a result, disease knowledge and therapeutic intervention has the potential to be more specific and customized to individual patients if the right molecular tests are developed, interpreted, and applied. Until recently, there have been no highly scalable solutions to provide this service at the point of care for individual patients.

With the support of CollabRx products and services, labs can provide to ordering physicians clinically interpretive content, personalized for each patient, as part of the reporting process. This not only makes the results of molecular tests more actionable, but it also provides a rationale for why specific tests should be ordered in the first place––thus making it more useful for ordering physicians. CollabRx content is dynamically updated every two weeks, ensuring that the most up-to-date information is available to support clinical decisions.

Healthcare Publishers

With the amount of healthcare-related information now readily available on the Internet, it is often difficult to differentiate between what is accurate and clinically relevant, and what is not. CollabRx’s mission is to change the practice of medicine by making thought-leader medicine accessible to all––providing actionable medical and scientific content to drive informed treatment decision-making.

Designed with all healthcare participants in mind, CollabRx’s products and services are tailored to fit the needs of patients and healthcare professionals alike. By providing the industry with interactive and highly credible Web-based and mobile platforms and applications, users now have unlimited access to the most up-to-date information on drugs, diagnostics, and clinical trials associated with specific molecular profiles.

Expert Affiliations

The CollabRx network of independent advisors is comprised of leading physicians, scientists, and researchers from the nation’s most prestigious academic and medical institutions as well as thought leaders spanning diverse backgrounds.

  • Banner MD Anderson Cancer Center,Gilbert, AZ
    Brigham And Women’s Hospital
    Cleveland Clinic Lerner College of Medicine
    Dana-Farber Cancer Institute
    Fred Hutchinson Cancer Research Center
    Fred Hutchinson/University of Washington Cancer Consortium
    Harvard Medical School
    Hollings Cancer Center
    Johns Hopkins Hospital and School of Medicine
    Massachusetts General Hospital
    Medical University of South Carolina
    Memorial Sloan Kettering Cancer Center
    Moores Cancer Center at UCSD
    National Cancer Institute
    New York University Langone Medical Center
    Northshore University of the University of Chicago
    Ohio State University Comprehensive Cancer Center
    Raboud University, Nijmegen, The Netherlands
    Seattle Cancer Care Alliance
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Bayview
    Stanford Cancer Institute
    Stanford University
    Stanford University School of Medicine
    University of Aberdeen
    University of British Columbia
    University of California, Los Angeles
    University of California, San Diego
    University of California, San Francisco
    University of California, San Francisco (Carol Franc Buck Breast Care Center)
    University of California, San Francisco (Helen Diller Family Comprehensive Cancer Center)
    University of California, San Francisco (School of Medicine)
    University of Chicago (Pritzker School of Medicine)
    University of Colorado
    University of Glasgow School of Medicine
    University of Pennsylvania
    University of Pennsylvania (Abramson Cancer Center)
    University of Pittsburgh Medical Center
    University of Texas (MD Anderson Cancer Center)
    University of Utah School of Medicine and Huntsman Cancer Institute
    University of Washington (School of Medicine)
    Vall d’Hebron University, Barcelona, Spain
    Weill Medical Collage of Cornell University
    Yale University

     


 

Products

Delivering Comprehensive Solutions

CollabRx develops products that inform treatment planning by changing the way medical and scientific information is organized, interpreted and disseminated with the goal of providing high value knowledge in an easily accessible form.

Clinical Products

CollabRx clinical products are point-of-care electronic resources to assist oncologists, other physicians and health care professionals, and cancer patients in creating a personalized treatment plan by leveraging the unique genetic profiles of a given patient’s tumor.

CancerRx™ App

The CancerRx™ app is a mobile clinical decision support resource designed to help physicians and their patients navigate the complex landscape of oncology therapeutic options. It currently offers expert-vetted guidance of treatment options (i.e., drugs, tumor genetic tests) for lung cancer, melanoma, metastatic breast cancer and colorectal cancer based on tumor genetic profiles, stage, and histology in addition to other important clinical parameters such as treatment history. In addition to treatment options based on the current standard of care, CancerRx helps physicians and patients identify the most relevant clinical trials of investigational therapies, and provides summaries and links to clinical findings published in top tier medical journals and presented at national conferences for oncologists and other physicians involved in the care of cancer patients. A special feature of CancerRx is a daily oncology newsfeed from MedPage Today, all with real-time over the air updates.

All knowledge is developed in close collaboration with CollabRx’s expert advisory network, which is composed of over 75 leading physicians, scientists, and researchers from the nation’s most prestigious academic and medical institutions as well as thought leaders spanning diverse backgrounds.

iTunes

Therapy Finder™ Applications

Therapy Finders are a series of Web-based expert system applications (“apps”) that enable physicians and their patients to learn which tests should be considered for tumor molecular analysis and how to use the results of those tests in evaluating therapy options including approved and investigational drugs and clinical trials.  The rationale for knowledge delivered via CollabRx Therapy Finders is transparent, associated with peer-reviewed publications, and generated by CollabRx scientific staff in collaboration with editorial boards of leading clinical practitioners.

Therapy Finder apps are freely accessible, provided for specific cancer types, and delivered in a form optimized for health care professionals (Professional version) and patients and caregivers (Patient version).  The Therapy Finder – Professional version is currently available for melanomacolorectal cancer, and lung cancer.  Other cancer types and Patient versions are in development. Also in development is an oncology-specific mobile app that will incorporate the Therapy Finders and ultimately serve as a comprehensive point of care resource for physicians and patients to obtain highly credible, expert-vetted and dynamically updated information to guide cancer treatment planning. Read the press release.

Laboratory Products

CollabRx is developing Web-based resources and apps to provide expert-vetted interpretation of molecular cancer panels, including clinical next-generation sequencing of tumors, in collaboration with our Pan Cancer molecular oncology Editorial Board.

Genetic Variant Annotation™ (GVA™) Service

The CollabRx GVA Service provides for a fully automated and scalable medical informatics solution to inform patient treatment planning by seamlessly pairing the results of genetic sequencing tests (generated on any platform) with clinically actionable and dynamically updated knowledge (provided by CollabRx in the form of interpretive reports).  Knowledge contained within GVA reports includes the clinical impact of specific genetic profiles and associated therapeutic strategies such as drugs and clinical trials.  This content leverages the CollabRx semantic integration platform, a proprietary technology that enables CollabRx scientists and physicians to dynamically update the company’s knowledge base with the latest medical and scientific data available in the public domain.  This knowledge is further contextualized in collaboration with CollabRx’s large and growing formal network of over 75 leading clinical practitioners in the U.S. and Europe.

Disease and Biomarker Coverage*
The GVA Service is currently available in oncology for all adult solid tumor types to support the clinical interpretation of tests to elucidate tumor mutation profiles generated on any testing platform, including next generation sequencing (NGS) devices. Tumor genetic alterations currently interpreted by the GVA Service include single base pair substitutions (missense and nonsense mutations) and nucleotide insertions and deletions (frameshift mutations). Support for other types of tumors (e.g., hematological malignancies) and genetic alterations (e.g., gene copy number variation (CNV), etc.) are in late stage development. There are hundreds of biomarkers and thousands of genetic alterations, drugs, and annotated clinical trials currently in the GVA knowledge base, all of which are linked to summary level information presented in a cancer type specific manner. This information directly supports clinical decision-making and includes expert-vetted statements describing clinical impact, therapeutic strategies, and potential drugs and clinical trials to consider during cancer treatment planning. Clinical guidelines, citations from the peer-reviewed medical and scientific literature, and other publicly available sources of information are provided in support of all information contained in GVA reports.

*Download an overview of the GVA Service. Detailed specifications and sample GVA reports are available upon request.

Delivery Model

Software-as-a-Service (SaaS)

  • One time set-up fee, annual maintenance fee, per-test fee
    Access via API
    Fully automated process; ideal for higher test volumes or larger labs
    Access via Web portal
    Semi-automated process; ideal for lower test volumes or smaller labs

Click here to see partner laboratories or contact us to to learn more about the GVA Service or other CollabRx products and services.


NanoVibronix

NanoVibronix Inc. is a medical device company that is focused on creating medical products utilizing its proprietary low intensity acoustic technology.

The company’s patented technology allows for creation of miniature transducers that transmit low-frequency, low-intensity ultrasound through flexible materials surfaces. This unique development may be utilized for a variety of additional medical applications requiring low cost therapeutic ultrasound qualities.

The company’s PainShield™ MD product has gained CE Mark certification and FDA clearance while the UroShield™ is currently CE mark certified.

NanoVibronix Inc. is located in Long Island, NY. Its subsidiary, NanoVibronix Ltd. is located in Nesher, Israel.

NANOVIBRONIX WEBSITE




 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CLRX
Current Price
Volume:
Bid Ask Day's Range
SureTrader
CLRX News: CollabRx Announces Adrienne Craig-Kennard as Vice President of Global Business Development and Strategic Alliances 01/19/2016 07:00:00 AM
CLRX News: CollabRx Chief Medical Officer to Moderate Panel at Personalized Medicine World Conference (PMWC) 2016 12/10/2015 07:00:00 AM
CLRX News: Initial Statement of Beneficial Ownership (3) 11/12/2015 04:19:10 PM
CLRX News: Initial Statement of Beneficial Ownership (3) 11/12/2015 03:19:00 PM
CLRX News: Initial Statement of Beneficial Ownership (3) 11/12/2015 02:55:49 PM
PostSubject
#1522   Lol. Did you write off yet? Jumpinjackas 12/14/15 09:35:05 AM
#1521   No sh@t sherlock darva 12/13/15 11:21:39 PM
#1520   It merged you fool Jumpinjackas 12/07/15 06:24:13 AM
#1519   Whats up with this POS? darva 12/06/15 10:07:09 PM
#1518   I would prefer not to invest in a divineinvestor 11/03/15 03:16:13 PM
#1517   At 1-for-2.5 to 1-for-10 What do you think DrShocker 11/02/15 09:42:22 PM
#1516   a reverse split of CollabRx's common stock at DrShocker 11/02/15 07:40:48 PM
#1515   The new combined entity will be known as DrShocker 11/02/15 07:38:12 PM
#1514   I just need the merger to go ahead divineinvestor 11/02/15 12:47:25 PM
#1513   Does anyone think that? Jumpinjackas 11/02/15 09:21:07 AM
#1512   I still have shares of clrx so I divineinvestor 11/02/15 08:33:15 AM
#1511   How fast you need a write off? Jumpinjackas 11/01/15 07:47:47 AM
#1510   CLRX or MMMS? DrShocker 11/01/15 07:04:56 AM
#1509   What equation is your opinion based off? 1-10 DC222 10/05/15 08:26:20 AM
#1508   $30k Jumpinjackas 10/05/15 06:49:20 AM
#1507   What will 100K shares of clrx be worth DC222 10/04/15 08:40:19 PM
#1506   Just wait until they merge with clorox Jumpinjackas 10/04/15 11:29:27 AM
#1505   SCAM! darva 09/23/15 08:38:38 PM
#1504   Why is that? pblax5 09/20/15 06:57:07 PM
#1503   Alright this party is about to get started, Tinee 09/16/15 06:05:19 PM
#1502   Unreal. They'll never get MMMS on Nasdaq. What pblax5 08/22/15 07:55:13 PM
#1501   clrx all time low, mmms is at 2.50. DC222 08/18/15 10:22:54 PM
#1500   you think it's a scam really? sh*t... pblax5 08/18/15 10:44:53 AM
#1499   Is there any lawsuits pending on this CLRX scam? DC222 08/14/15 05:05:45 PM
#1498   You never loose only gain-) I saw that DC222 07/27/15 09:22:07 AM
#1497   yes the symbol will change. you should get pblax5 07/25/15 07:46:37 PM
#1496   Are you saying that they will not trade DC222 07/24/15 02:37:14 PM
#1495   MMMS released a pr last week. it was pblax5 07/24/15 10:25:42 AM
#1494   What news are you talking about? DC222 07/20/15 08:23:06 PM
#1493   Finally! And it sounds like they have to pblax5 07/18/15 05:26:55 PM
#1492   Merger News! smitter 07/17/15 05:26:28 PM
#1491   whats up with this POS scam? darva 07/08/15 10:44:52 AM
#1490   Maybe Seamus Lagan and frank and seamus' girlfriend pblax5 07/06/15 05:19:26 PM
#1488   you and me both my friend. when the hookedontonics 06/26/15 10:26:26 AM
#1487   I hope this is the move we've been MyDosCentavos 06/26/15 10:12:11 AM
#1486   good question. we all know what's coming...i honestly hookedontonics 06/26/15 10:02:22 AM
#1485   I dont' see news, wonder what is up? Tinee 06/26/15 10:01:06 AM
#1484   Movement detected... Dubs_Swagu 06/26/15 09:41:55 AM
#1483   .839 after hours...expecting news here in the next hookedontonics 06/16/15 06:33:49 PM
#1482   I wonder if they will do earnings due Tinee 06/12/15 08:21:01 AM
#1481   Hopefully earnings report EOD: http://www.fredericknewspost.com/news/econom Dubs_Swagu 06/09/15 02:37:46 PM
#1480   Does CLRX have any affiliation with HEME? longview1 06/03/15 01:11:42 PM
#1479   @ $seeker....sorry I dont have Private msg.... 123tom 06/03/15 12:55:06 PM
#1478   If the merger goes through as planned then DC222 05/20/15 09:26:51 PM
#1477   .80 to 1.20 50% CLRX play??? UserAlias1 05/20/15 05:27:10 PM
#1476   news should still be a couple weeks out hookedontonics 05/20/15 09:52:24 AM
#1475   I hope so. Got my left one invested mh1156 05/20/15 08:46:15 AM
#1474   News expected? There was a huge after market Tinee 05/20/15 08:25:01 AM
#1473   nice hookedontonics 05/19/15 08:54:31 AM
#1472   http://www.nasdaq.com/quotes/institutional-portfolio/sabby-management-llc-871441 Tinee 05/19/15 08:43:09 AM
PostSubject